



The Silent Crossroad: Systemic Pharmacotherapy and Its Implications on Oral Health

*S. Mitthra

Department of Conservative Dentistry and Endodontics, SRM Kattankulathur Dental College and Hospital, SRM Institute of Science and Technology, Chennai- 603203, Tamil Nadu, India

*Corresponding author: Dr. S. Mitthra, Professor and Research Coordinator, SRM Kattankulathur Dental College and Hospital, SRM Institute of Science and Technology, Chennai- 603203, Tamil Nadu, India: Email: mitthras@srmist.edu.in

Article Info

Received: 28.08.2026

Accepted: 26.09.2026

Published: 13.10.2026



© 2026 by the authors. The terms and conditions of the Creative Commons Attribution (CC BY) license

INTRODUCTION

The human oral cavity serves as an exceptionally sensitive barometer of the general physical well-being of any individual. Historically, medicine and dentistry operated within distinct professional categories; however, modern clinical science increasingly demands a unified interdisciplinary paradigm. As pharmacotherapy continues to evolve with remarkable precision and sophistication, the systemic administration of therapeutics frequently exerts secondary, adverse effects on the oral tissues [1]. From medication-induced hyposalivation to the complex soft-tissue mucosal reactions and alveolar bone homeostasis disruptions, systemic drug therapies profoundly influence oral physiology. For pharmaceutical scientists, pharmacologists, and dental professionals, understanding the multifaceted relationship between drugs and oral health is no longer merely an academic exercise it is an indispensable clinical imperative [2].

Salivary Dysfunction and the Xerostomia

Saliva is fundamental to the maintenance of the oral ecosystem. Rich in antimicrobial proteins, immunoglobulins, buffering bicarbonates, and remineralizing ions, a healthy salivary flow preserves mucosal integrity and protects dental hard tissues against acidic degradation. The most prevalent oral adverse effect associated with systemic pharmacotherapy is xerostomia (subjective dry mouth) and objective salivary gland hypofunction. Over 500 prescription and over-the-counter medications are known to induce salivary dysfunction.

Keywords Oral cavity, Editorial Note, Hypofunction, Pharmacotherapy, Xerostomia.

Anticholinergic Pathways: Drugs possessing anticholinergic or antimuscarinic properties such as tricyclic antidepressants, typical and atypical antipsychotics, antihistamines, and bladder antispasmodics competitively inhibit muscarinic (M3) receptors within the acinar cells of the salivary glands. This inhibition halts fluid secretion, yielding a dry, friable mucosa.

Sympathomimetic and Central Mechanisms: Antihypertensives (such as central alpha agonists and beta-blockers), sedatives, and chronic opioid therapies further alter fluid and electrolyte transport across acinar membranes or suppress central salivary nuclei.

The sequelae of chronic hyposalivation extend far beyond the momentary discomfort. Deprived of normal clearance and buffering capacity, most patients experience a rapid surge in

acidogenic microbiota (*Streptococcus mutans* and *Lactobacillus* species), leading to rampant root caries and cervical caries. Furthermore, the loss of lubricating mucins predisposes the patients to painful oral candidiasis, burning mouth symptoms, dysgeusia (taste distortion), and severe difficulty with mastication, deglutition, and speech [3,4].

Drug-Induced Mucosal Alterations and Hypersensitivity

The oral mucosa exhibits high cellular proliferation, making it particularly susceptible to therapeutic agents that modify the immune responses or cellular kinetics.

1. Lichenoid Drug Eruptions

A vast array of systemic drugs can induce oral lichenoid reactions, which clinically and histologically mimic erosive or

reticular oral lichen planus. The common pharmacological classes include: Non-steroidal anti-inflammatory drugs (NSAIDs). Angiotensin-converting enzyme (ACE) inhibitors. Beta-blockers. Oral hypoglycemic agents (e.g., sulfonylureas)

These reactions represent a delayed cell-mediated hypersensitivity response, wherein drug metabolites act as haptens, triggering CD8⁺ T-cell cytotoxicity against basal keratinocytes [5,6,7].

2. Mucositis and Cytotoxic Insults

Chemotherapeutic anti-neoplastic agents (such as 5-fluorouracil, methotrexate, and doxorubicin) non-selectively suppress rapidly dividing epithelial cells. This results in severe, debilitating oral mucositis characterized by widespread mucosal atrophy, painful ulcerations, and haemorrhage. These ulcerative sites serve as portals of entry for secondary systemic opportunistic infections, often necessitating reductions or delays in cancer treatment regimens [8].

3. Vesiculobullous and Ulcerative Reactions

Targeted biological therapies, immune checkpoint inhibitors, and conventional antibiotics (e.g., penicillins and sulfonamides) can provoke severe immunologically mediated cutaneous and mucosal reactions, including Erythema Multiforme, Stevens-Johnson Syndrome (SJS), and Toxic Epidermal Necrolysis (TEN) [9].

Drug-Induced Gingival Overgrowth (DIGO)

Gingival enlargement is a well-characterized adverse reaction caused primarily by three distinct drug classes: Anticonvulsants: Phenytoin, Immunosuppressants: Cyclosporine A, Calcium Channel Blockers: Nifedipine, Diltiazem, and Amlodipine. While these drugs differ significantly in their primary systemic mechanisms, their adverse effects on the gingival connective tissue share common pathways:

Pathophysiology: These agents modulate intracellular calcium flux and alter matrix metalloproteinase (MMP) activity in the gingival fibroblasts. This results in an imbalance between collagen synthesis and degradation, leading to an excessive accumulation of extracellular matrix, particularly glycosaminoglycans and collagen fibres.

Clinical Impact: The resulting tissue enlargement creates pseudo-pockets that hinder routine plaque removal. Secondary microbial plaque accumulation induces severe gingival inflammation, bleeding, and accelerated breakdown of the underlying periodontium [10,11].

Hard Tissue Disruptions and Bone Metabolism

The emergence of Medication-Related Osteonecrosis of the Jaw, highlights the critical need for interdisciplinary risk management. Non-healing exposed alveolar bone in patients receiving antiresorptive or anti-angiogenic agents for osteoporosis or bone metastases underlines why dental clearance must precede the initiation of high-dose antiresorptive therapy whenever possible (Table 1).

Table 1. Systemic medications also exert profound effects on the osseous structures supporting the dentition.

Drug Class	Key Mechanism	Primary Oral Effect / Concern
Anti-resorptives (<i>Bisphosphonates, Denosumab</i>)	Inhibit osteoclast function & bone remodelling	Medication-Related Osteonecrosis of the Jaw following invasive dental procedures
Systemic Corticosteroids	Suppress osteoblast differentiation & intestinal Ca ²⁺ absorption	Rapid alveolar bone loss, osteoporosis, impaired surgical wound healing
Tetracyclines	Chelate calcium during mineralization phases	Intrinsic tooth discoloration and enamel hypoplasia in developing dentition

The Path Forward: Pharmacovigilance and Collaborative Care

As new pharmacological entities including monoclonal antibodies, kinase inhibitors, and advanced gene therapies enter clinical practice, unexpected oral adverse drug reactions will continue to emerge.

Integrated Pharmacovigilance: Pharmaceutical scientists and clinical pharmacologists must actively analyse oral adverse events during preclinical evaluations and post-marketing surveillance phases.

Cross-Disciplinary Education: Medical education must integrate oral health concepts, while dental curricula must deepen coverage of clinical pharmacology, pharmacokinetics, and drug-drug interactions.

Proactive Management Protocols: Clinicians must perform comprehensive medication reviews before initiating therapies known to cause xerostomia, gingival enlargement, or mucosal lesions. Implementing preventive strategies such as topical

fluoride treatments, sialagogues, and tailored oral hygiene regimens can significantly reduce the adverse drug reactions [12-16].

CONCLUSION

The oral cavity cannot be viewed in isolation from the rest of the human body. Every prescribed drug molecule carries the potential to subtly re-shape or disrupt the delicate equilibrium of the oral environment. As the *Tamil Nadu Journal of Pharmaceutical Research* embarks on this exciting editorial chapter, we reaffirm our dedication to bridging pharmaceutical innovation with holistic, patient-centered clinical practice. By fostering rigorous interdisciplinary research, promoting proactive pharmacovigilance, and translating benchtop discoveries into clinical solutions, we can ensure that advances in systemic medicine preserve and protect oral health.

REFERENCES

1. Leo, M., D'Angeli, F., Genovese, C., Spila, A., Miele, C., Ramadan, D., Ferroni, P., & Guadagni, F. (2024). Oral Health and Nutraceutical Agents. *International journal of molecular sciences*, 25(17), 9733. <https://doi.org/10.3390/ijms25179733>
2. Deng, L., Guan, G., Cannon, R. D., & Mei, L. (2025). Age-related oral microbiota dysbiosis and systemic diseases. *Microbial pathogenesis*, 205, 107717. <https://doi.org/10.1016/j.micpath.2025.107717>
3. Visvanathan, V., & Nix, P. (2010). Managing the patient presenting with xerostomia: a review. *International journal of clinical practice*, 64(3), 404-407. <https://doi.org/10.1111/j.1742-1241.2009.02132.x>
4. Furness, S., Worthington, H. V., Bryan, G., Birchenough, S., & McMillan, R. (2011). Interventions for the management of dry mouth: topical therapies. *The Cochrane database of systematic reviews*, 2011(12), CD008934. <https://doi.org/10.1002/14651858.CD008934.pub2>
5. Carrozzo, M., Porter, S., Mercadante, V., & Fedele, S. (2019). Oral lichen planus: A disease or a spectrum of tissue reactions? Types, causes, diagnostic algorithms, prognosis, management strategies. *Periodontology 2000*, 80(1), 105–125. <https://doi.org/10.1111/prd.12260>
6. Scully, C., & Bagan, J. V. (2004). Adverse drug reactions in the orofacial region. *Critical reviews in oral biology and medicine: an official publication of the American Association of Oral Biologists*, 15(4), 221–239. <https://doi.org/10.1177/154411130401500405>
7. Al-Hashimi, I., Schifter, M., Lockhart, P. B., Wray, D., Brennan, M., Migliorati, C. A., Axéll, T., Bruce, A. J., Carpenter, W., Eisenberg, E., Epstein, J. B., Holmstrup, P., Jontell, M., Lozada-Nur, F., Nair, R., Silverman, B., Thongprasom, K., Thornhill, M., Warnakulasuriya, S., & van der Waal, I. (2007). Oral lichen planus and oral lichenoid lesions: diagnostic and therapeutic considerations. *Oral surgery, oral medicine, oral pathology, oral radiology, and endodontics*, 103 Suppl, S25.e1–S25.e12. <https://doi.org/10.1016/j.tripleo.2006.11.001>
8. Stone, R., Flidner, M. C., & Smiet, A. C. (2005). Management of oral mucositis in patients with cancer. *European journal of oncology nursing: the official journal of European Oncology Nursing Society*, 9 Suppl 1, S24–S32. <https://doi.org/10.1016/j.ejon.2005.08.004>
9. Auquier-Dunant, A., Mockenhaupt, M., Naldi, L., Correia, O., Schröder, W., Roujeau, J. C., & SCAR Study Group. Severe Cutaneous Adverse Reactions (2002). Correlations between clinical patterns and causes of erythema multiforme majus, Stevens-Johnson syndrome, and toxic epidermal necrolysis: results of an international prospective study. *Archives of dermatology*, 138(8), 1019–1024. <https://doi.org/10.1001/archderm.138.8.1019>
10. Zhang, R., Wu, J., Zhu, J., Wang, X., & Song, J. (2022). Bibliometric analysis of research trends and characteristics of drug-induced gingival overgrowth. *Frontiers in public health*, 10, 979861. <https://doi.org/10.3389/fpubh.2022.979861>
11. Nanda, T., Singh, B., Sharma, P., & Arora, K. S. (2019). Cyclosporine A and amlodipine induced gingival overgrowth in a kidney transplant recipient: case presentation with literature review. *BMJ Case Reports*, 12(5), e229587. <https://doi.org/10.1136/bcr-2019-229587>
12. AlDhalaan, N. A., BaQais, A., & Al-Omar, A. (2020). Medication-related Osteonecrosis of the Jaw: A Review. *Cureus*, 12(2), e6944. <https://doi.org/10.7759/cureus.6944>
13. Cho, J., Feldman, G., Tomlinson, R., Taub, D., & Diecidue, R. (2024). Medication-related osteonecrosis of the jaw (MRONJ) systemic review: mevalonate pathway mechanisms explored. *Oral surgery, oral medicine, oral pathology and oral radiology*, 138(4), 475–483. <https://doi.org/10.1016/j.oooo.2024.05.014>
14. Frutuoso, F., Freitas, F., Vilares, M., Francisco, H., Marques, D., Caramês, J., & Moreira, A. (2024). Medication-Related Osteonecrosis of the Jaw: A Systematic Review of Case Reports and Case Series. *Diseases (Basel, Switzerland)*, 12(9), 205. <https://doi.org/10.3390/diseases12090205>
15. Kuroshima, S., Sasaki, M., & Sawase, T. (2019). Medication-related osteonecrosis of the jaw: A literature review. *Journal of oral biosciences*, 61(2), 99–104. <https://doi.org/10.1016/j.job.2019.03.005>
16. Zhang, R., Wu, J., Zhu, J., Wang, X., & Song, J. (2022). Bibliometric analysis of research trends and characteristics of drug-induced gingival overgrowth. *Frontiers in Public Health*, 10, 979861. <https://doi.org/10.3389/fpubh.2022.979861>